Navigation Links
Reportlinker Adds Targeted Therapeutics- Advancement in Gene Therapy and Stem Cell Therapy will Drive the Market
Date:2/17/2011

NEW YORK, Feb. 17, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Targeted Therapeutics- Advancement in Gene Therapy and Stem Cell Therapy will Drive the Market

http://www.reportlinker.com/p0397055/Targeted-Therapeutics--Advancement-in-Gene-Therapy-and-Stem-Cell-Therapy-will-Drive-the-Market.html

Targeted Therapeutics- Advancement in Gene Therapy and Stem Cell Therapy will Drive the Market

Summary

GBI Research, the leading business intelligence provider, has released its latest research "Targeted Therapeutics- Advancement in Gene Therapy and Stem Cell Therapy will Drive the Market". The report provides in-depth analysis of the major targeted therapeutics. The Market Drivers and Restraints for all the types of Targeted Therapeutics (TT) are analyzed. The report provides comprehensive assessment of key pipeline therapies in the TT segment. The profiles of key promising molecules in the pipeline are mentioned. The regulatory Landscape is analyzed with focus on European and the US scenario. The regulatory landscape details about the major agencies for gene and stem cell therapies. The report profiles all the key companies dealing in TT with main focus on their deals involving M&A and licensing deals.

GBI Research finds that TT is the need of the hour for biotech and pharmaceutical companies to recover from the loss of revenue by patent expiry of conventional blockbuster drugs. Thus key pipeline molecules and key deals will help the companies to make a better future strategy.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.

The report gives insight about the key deals which have taken place between biopharmaceutical companies and their influence. Reasons for considering strategic consolidation as the main objective of the companies have been mentioned. The major types of TT include small molecule drugs, protein/peptide therapeutics, monoclonal antibody therapeutics, RNA interference, gene therapy and stem cell therapy. The market drivers and restraints for these six classes are mentioned. From a commercial perspective there is a huge unmet medical need in difficult to treat diseases like cancer and autoimmune diseases. The unmet need is due to the lack of effective and efficacious therapies based on conventional mode of research. TT has the potential to satisfy this unmet need by being more efficacious, effective and safe. The strategic M&A deals and licensing deals of key companies such as Eli Lilly, Forest Laboratories, Hoffmann La-Roche, Isis Pharmaceuticals, J&J, Pfizer , Biogen, Antisoma and others are analyzed.

Scope

The scope of this report includes -

- Description of major types of TT with key market drivers and restraints.

- Analysis of the leading pipeline therapies which will define the future of TT market.

- Factors driving small molecule drugs, peptide/protein drugs, MAbs, RNA interference therapeutics, gene and stem cell therapy are analyzed.

- Key Regulatory Landscape is detailed for understanding the approval procedure of TT with main focus on gene and stem cell therapy.

- Major companies dealing in TT are profiled and their M&A and Licensing deals are mentioned.

- Key companies studied in this report are Eli Lilly, Pfizer, J&J, Hoffmann La- Roche, Biogen, Isis Pharmaceuticals and Antisoma.

Reasons to buy

The report will enhance your decision making capability. It will allow you to -

- Identify the advantages of TT and understand the potential that it can capture.

- Align your product portfolio to the TT market segment with high growth potential.

- Develop market-entry and market expansion strategies by identifying the leading TT segments poised for strong growth.

- Understand the key risks and issues which TT is facing and key solutions in development to address these issues.

- Develop key strategic initiatives by understanding the key focus areas with respect to pipeline portfolio of leading companies.

- Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio gaps and lead to revenue generation.

- Identify key players best positioned to take advantage of TT market potential.

To order this report:

: Targeted Therapeutics- Advancement in Gene Therapy and Stem Cell Therapy will Drive the Market

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Nicolas Bombourg

Reportlinker

Email: nbo@reportlinker.com

US: (805)652-2626

Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Reportlinker Adds Frontiers in Carbohydrates Developments: Report 4; Research, Technologies; Biotechnology, Bioprocessing & Bioplastics - Food & Industrial Raw Material, January 2011
2. Reportlinker Adds Pipeline Insight: Cancer Overview- Breast and Gynecological Cancers - Promising agents emerge for BRCA positive patients
3. Reportlinker Adds Strategic Analysis of European Human Machine Interface (HMI) Market
4. Reportlinker Adds Amphotericin B - Comprehensive patent search
5. Reportlinker Adds Therapeutic Proteins to 2014
6. Reportlinker Adds Biochips - Products, Applications, Technologies and End-Use Markets Growth Analysis, 2009-2015
7. Reportlinker Adds Cell Therapy - Technologies, Markets and Companies
8. Reportlinker Adds The 2011 Molecular Diagnostics Market: DNA Probes and Biochips -- New Product Development Opportunities and Business Expansion Strategies for Instrument and Reagent Suppliers
9. Reportlinker Adds The 2011 Immunoprotein Diagnostics Market: US, Europe, Japan Test Volume and Sales Forecasts by Country and Market Segment
10. Reportlinker Adds The 2011 Clinical Chemistry and Immunodiagnostics Markets: US, Europe, Japan Product Development Opportunities and Business Expansion Strategies for Instrumentand Reagent Suppliers
11. Reportlinker Adds Biologic Therapeutic Drugs: Technologies and Global Markets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 23, 2016  Blueprint Bio, a company dedicated to ... medical community, has closed its Series A funding round, ... "We have received a commitment from Forentis ... need to meet our current goals," stated Matthew ... runway to complete validation on the current projects in ...
(Date:6/23/2016)... On Wednesday, June 22, 2016, the NASDAQ Composite ... Jones Industrial Average edged 0.27% lower to finish at 17,780.83; ... has initiated coverage on the following equities: Infinity Pharmaceuticals Inc. ... NKTR ), Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ ), ... more about these stocks by accessing their free trade alerts ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... on quality, regulatory and technical consulting, provides a free webinar on ... on July 13, 2016 at 12pm CT at no charge. , Incomplete investigations ...
(Date:6/23/2016)... SAN FRANCISCO , June 22, 2016  Amgen ... platinum sponsorship of the QB3@953 life sciences ... improve human health. The shared laboratory space at QB3@953 ... startups overcome a key obstacle for many early stage ... As part of the sponsorship, Amgen launched two "Amgen ...
Breaking Biology Technology:
(Date:4/28/2016)... First quarter 2016:   , Revenues amounted to ... of 2015 The gross margin was 49% (27) ... operating margin was 40% (-13) Earnings per share rose ... was SEK 249.9 M (21.2) , Outlook   ... The operating margin for 2016 is estimated to exceed ...
(Date:4/19/2016)... The new GEZE SecuLogic access ... "all-in-one" system solution for all door components. It can ... door interface with integration authorization management system, and thus ... minimal dimensions of the access control and the optimum ... offer considerable freedom of design with regard to the ...
(Date:4/14/2016)... 2016 BioCatch ™, the ... announced the appointment of Eyal Goldwerger as ... Goldwerger,s leadership appointment comes at a time of ... deployment of its platform at several of the world,s ... discerns unique cognitive and physiological factors, is a winner ...
Breaking Biology News(10 mins):